H.C. Wainwright Remains a Buy on BioCryst (BCRX)


H.C. Wainwright analyst Andrew Fein maintained a Buy rating on BioCryst (BCRX) today and set a price target of $13. The company’s shares opened today at $8.47.

Fein wrote:

“Valuation and risks to achievement of price target. Our price target of $13 is based on the following risk-adjusted sum-of parts NPV-DCF: $10.2 for oral HAE prophylactic treatment + $1.1 for oral liquid HAE acute treatment + $0.3 for peramivir + $1.5 in cash. We assume a discount rate of 13.5%.”

According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.3% and a 47.9% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

BioCryst has an analyst consensus of Moderate Buy, with a price target consensus of $14.50.

See today’s analyst top recommended stocks >>

Based on BioCryst’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $29.6 million. In comparison, last year the company had a GAAP net loss of $19.54 million.

Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. Most recently, in December 2018, Alane Barnes, the SVP, Chief Legal Officer of BCRX sold 44,290 shares for a total of $401,710.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The firm focusses on oral treatments for rare diseases. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430. These drugs intend to treat influenza and hereditary angioedema.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts